Close up of Asian women with hi tech digital technology screen over the eye.
Our Work

Latham Advises Eurazeo on Its Contemplated Sale of D.O.R.C. For An Enterprise Value of €985 Million

January 9, 2024
Cross-border team represents the European investment group in the transaction.

Latham & Watkins has advised Eurazeo, a leading European investment group listed on Euronext Paris, in the context of its entering into exclusive discussions with Carl Zeiss Meditec AG, a leading medical technology company listed on the MDAX and TecDAX of the German stock exchange, for the sale of its stake in D.O.R.C (Dutch Ophthalmic Research Center), one of the world’s leading suppliers of instruments and equipment for vitreoretinal surgery headquartered in the Netherlands, for an enterprise value of approximately €985 million.

The transaction remains subject to completion of the information and consultation process with D.O.R.C.'s relevant employee representative bodies, and obtaining applicable regulatory approvals.

The Latham team was led by Paris partners Thomas Forschbach and Alexander Benedetti, with associates François Blanchet, Jacek Urban, Claudia Reix, and Nicolas Lacour. Advice was also provided on finance matters by Paris partners Xavier Farde and Carla-Sophie Imperadeiro; on tax matters by Paris partner Xavier Renard, with associate Clémence Morel; on healthcare and life sciences matters by Paris partner Eveline Van Keymeulen, with associate Jeanne Fabre; and on English and US law matters by London corporate partner Maarten Overmars and Washington, D.C. counsel Chad Jennings.